6:07 PM
 | 
Jun 10, 2009
 |  BC Extra  |  Company News

FDA wants new Qutenza trial

NeurogesX Inc. (NASDAQ:NGSX) said FDA requested an additional trial as part of its review of an NDA for Qutenza to manage pain associated with post-herpetic neuralgia (PHN). The company said that given the short-term nature of the trial, it might...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >